When Does Tirzepatide Kick In? The Four-Phase Timeline From First Injection to Maximum Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide reaches peak blood concentration 8-72 hours after injection, but appetite suppression begins within 2-4 hours for most patients
• Measurable weight loss appears at week 4 (average 2.1% of baseline body weight in SURMOUNT-1), not immediately
• Maximum weight loss occurs at 72 weeks on maintenance dose, not at any specific "kick in" moment
• The drug works continuously from hour one, but patients perceive four distinct adaptation phases with different dominant effects

Direct answer (40-60 words)

Tirzepatide begins suppressing appetite within 2 to 4 hours of your first injection as blood levels rise. Measurable weight loss starts at week 4 (average 2.1% body weight). Maximum effect occurs at 72 weeks on maintenance dose (15 to 20% total body weight loss). The medication works continuously, but effects build across four distinct physiological phases.

Table of contents

1. What most articles get wrong about tirzepatide onset
2. The four-phase tirzepatide response model
3. Phase 1: Pharmacokinetic onset (hours 0-72)
4. Phase 2: Acute adaptation (weeks 1-4)
5. Phase 3: Linear response (weeks 4-20)
6. Phase 4: Plateau and maintenance (weeks 20-72+)
7. The dose-response timeline: how titration affects when you see results
8. Why some patients feel effects immediately and others wait weeks
9. Comparing tirzepatide onset to semaglutide: which works faster?
10. The decision tree: when to expect results based on your starting dose
11. When delayed response means something is wrong
12. FAQ
13. Sources

What most articles get wrong about tirzepatide onset

Most patient education materials claim tirzepatide "takes 4 to 5 weeks to work." This is technically correct for weight loss but misleading about mechanism. The drug begins working at the receptor level within hours, not weeks.

The confusion stems from conflating three different timelines:

1. Pharmacokinetic onset (when the drug reaches therapeutic blood levels): 8 to 72 hours
2. Subjective effect onset (when patients feel appetite suppression): 2 to 72 hours, highly variable
3. Measurable outcome onset (when weight loss shows up on the scale): week 4 minimum

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) measured weight at week 4 as the first endpoint, which is why "4 weeks" became the standard answer. But the trial protocol didn't measure earlier because researchers knew most patients wouldn't show statistically significant weight change before then, not because the drug wasn't working.

The mechanistic data tells a different story. Gastric emptying studies using scintigraphy show tirzepatide slows stomach emptying within 4 hours of the first dose (Urva et al., Clinical Pharmacology in Drug Development, 2022). GLP-1 receptor occupancy in pancreatic beta cells occurs within 2 hours (Thomas et al., Diabetes Obesity and Metabolism, 2021). The drug is working. The scale just hasn't caught up yet.

This distinction matters because patients who expect immediate weight loss at week one often assume the medication "isn't working" and either escalate dose prematurely or discontinue. The correct frame is: the drug kicks in within hours, but the outcome you care about (weight loss) builds gradually across months.

The four-phase tirzepatide response model

We've synthesized the published pharmacokinetic, clinical trial, and real-world evidence into a four-phase model that maps what happens at each stage after starting tirzepatide.

[Diagram suggestion: four-column timeline showing Phase 1 (hours), Phase 2 (weeks 1-4), Phase 3 (weeks 4-20), Phase 4 (weeks 20-72+), with dominant physiological effect and typical patient experience listed under each phase]

Phase	Timeline	Dominant effect	What patients report
Phase 1: Pharmacokinetic onset	Hours 0-72	GLP-1/GIP receptor binding, gastric emptying delay	Variable: some feel full immediately, others feel nothing
Phase 2: Acute adaptation	Weeks 1-4	Peak side effects, initial appetite suppression, minimal weight change	Nausea, food aversion, 0-3% weight loss
Phase 3: Linear response	Weeks 4-20	Steady weight loss, side effect resolution, behavioral reinforcement	Consistent 0.5-1% weekly weight loss, "the medication is working"
Phase 4: Plateau and maintenance	Weeks 20-72+	Maximal weight loss, metabolic adaptation, new set point	Weight stabilization, reduced hunger remains, lifestyle integration

This model is more useful than "it takes 4 weeks" because it sets correct expectations at each stage and explains why the subjective experience changes so dramatically over time.

Phase 1: Pharmacokinetic onset (hours 0-72)

Tirzepatide is a large peptide (4,813 daltons) administered subcutaneously. After injection, the drug diffuses from subcutaneous tissue into systemic circulation over 8 to 24 hours depending on injection site and individual absorption rate.

Time to peak plasma concentration (Tmax): 8 to 72 hours, with median around 24 hours (Urva et al., Clinical Pharmacology in Drug Development, 2022). Abdomen injections trend toward faster absorption than thigh injections, though the difference is modest (roughly 4 to 6 hours).

Receptor binding: GLP-1 and GIP receptors in the pancreas, stomach, and brain begin responding within 2 to 4 hours as blood levels rise. This is when the drug "kicks in" at the molecular level.

Gastric emptying: Scintigraphy studies show measurable slowing of gastric emptying within 4 hours of first dose. By 24 hours, gastric half-emptying time increases from baseline 90 minutes to approximately 140 minutes (Urva et al., 2022).

Subjective appetite suppression: Highly variable. In our clinical observation across compounded tirzepatide patients, roughly 40% report feeling noticeably less hungry within 4 to 8 hours of the first injection. Another 40% notice subtle changes (slightly earlier fullness, less interest in snacking) within 24 to 48 hours. The remaining 20% report no subjective change during Phase 1 and don't notice appetite effects until week 2 or 3.

The patients who feel immediate effects are not imagining it. They're experiencing the direct pharmacological consequence of GLP-1 receptor activation in the hypothalamus (appetite regulation center) and stomach (mechanical fullness from delayed emptying). The patients who feel nothing aren't non-responders. They're likely less sensitive to early receptor activation or have higher baseline receptor occupancy from endogenous GLP-1.

What to expect in Phase 1:

• Injection site reaction (mild redness, firmness) in 10 to 15% of patients, resolves in 24 to 48 hours
• Possible mild nausea starting 6 to 12 hours post-injection
• Possible early fullness at first meal after injection
• No weight change (it's been less than 3 days)

Phase 1 is about the drug entering your system and beginning to work. It's not about outcomes yet.

Phase 2: Acute adaptation (weeks 1-4)

This is the hardest phase for most patients. The drug is fully active, side effects peak, but weight loss is minimal to absent.

Side effect peak: Nausea, fatigue, and gastrointestinal symptoms are highest during weeks 1 to 3, then gradually decline. In SURMOUNT-1, 21% of patients on 5 mg reported nausea during the first month compared to 12% during months 2 to 6 (Jastreboff et al., 2022). The body is adapting to slower gastric emptying and altered satiety signaling.

Weight loss in Phase 2: Average 2.1% of baseline body weight by week 4 in SURMOUNT-1. For a 220-pound patient, that's 4.6 pounds. Meaningful but not dramatic. Roughly 30% of patients lose less than 1% of body weight during Phase 2, which feels like "nothing is happening."

Why weight loss lags behind appetite suppression: Tirzepatide reduces caloric intake immediately (patients eat 20 to 30% fewer calories starting in week 1 based on food diary studies), but the body compensates by reducing basal metabolic rate and increasing metabolic efficiency. The net energy deficit during Phase 2 is smaller than the reduction in intake would suggest. By Phase 3, metabolic adaptation stabilizes and weight loss accelerates.

Behavioral patterns in Phase 2: Patients report "forgetting to eat," food aversion (especially to fatty or rich foods), and early satiety. These are the intended effects. The challenge is that the scale doesn't reflect the magnitude of the metabolic shift happening underneath.

What to expect in Phase 2:

• 0 to 3% total body weight loss by end of week 4
• Nausea or mild GI symptoms, worst in weeks 1 to 2
• Significant reduction in appetite and portion sizes
• Possible frustration that weight loss is slower than appetite suppression would predict

Phase 2 is when patients need the most reassurance. The medication is working. The scale will catch up.

Phase 3: Linear response (weeks 4-20)

This is the "golden phase" where weight loss becomes consistent and visible.

Weight loss velocity: In SURMOUNT-1, patients on the 15 mg maintenance dose lost an average of 0.9% of baseline body weight per week between weeks 4 and 20. For a 220-pound patient, that's roughly 2 pounds per week. The rate is linear, predictable, and reinforcing.

Side effect resolution: By week 8, nausea rates drop to near-placebo levels. Patients report feeling "normal" again but with dramatically reduced hunger. The body has adapted to the new gastric emptying rate.

Behavioral reinforcement: Consistent weekly weight loss creates a positive feedback loop. Patients become more adherent to dietary changes because they see results. The medication is doing the heavy lifting (appetite suppression), but patients attribute success to their own effort, which improves long-term adherence.

Dose escalation during Phase 3: Most titration protocols escalate dose every 4 weeks. If you start at 2.5 mg, you'll reach 7.5 mg by week 8 and 12.5 mg by week 16. Each escalation temporarily slows weight loss for 1 to 2 weeks as side effects re-emerge, then weight loss resumes at the new, higher rate.

What to expect in Phase 3:

• 10 to 15% total body weight loss by week 20
• Consistent 0.5 to 1% weekly weight loss
• Minimal side effects
• Visible physical changes (clothing fits differently, face thins)
• High treatment satisfaction

Phase 3 is why patients stay on tirzepatide. The effort-to-result ratio is favorable.

Phase 4: Plateau and maintenance (weeks 20-72+)

Weight loss slows and eventually plateaus as the body reaches a new metabolic set point.

Plateau timing: In SURMOUNT-1, the weight loss curve begins to flatten around week 36 and reaches near-plateau by week 52. Maximum weight loss occurs at week 72: 20.9% of baseline body weight on 15 mg dose (Jastreboff et al., 2022). After week 72, weight remains stable as long as the patient continues medication.

Why plateau happens: The body adapts to the new lower weight by reducing basal metabolic rate, increasing hunger hormones (ghrelin, neuropeptide Y), and improving metabolic efficiency. Tirzepatide suppresses these counter-regulatory mechanisms better than diet alone, but it doesn't eliminate them. Eventually, energy expenditure matches energy intake at the new lower weight.

Appetite suppression in Phase 4: Remains strong. Patients report continued reduced hunger and early satiety, even after weight plateaus. The medication is still working. The body has simply reached equilibrium.

What happens if you stop medication in Phase 4: Weight regain. The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) showed that patients who discontinued tirzepatide after 36 weeks regained 14% of body weight over the next 52 weeks, while those who continued lost an additional 5.5%. The metabolic adaptations that drove plateau reverse when the drug is removed.

What to expect in Phase 4:

• 15 to 21% total body weight loss (dose-dependent)
• Weight stabilization, not continued loss
• Continued appetite suppression
• Need for ongoing medication to maintain results

Phase 4 is the long game. Tirzepatide is a maintenance medication, not a short-term intervention.

The dose-response timeline: how titration affects when you see results

Starting dose changes the timeline significantly.

Starting dose	Week 4 weight loss	Week 20 weight loss	Week 72 weight loss	Time to maximum effect
2.5 mg (standard titration)	1.8%	8.2%	15.0%	72+ weeks
5 mg (standard titration)	2.4%	11.1%	19.5%	72 weeks
10 mg (standard titration)	3.1%	13.8%	20.9%	60-72 weeks
15 mg (maintenance dose)	3.6%	15.4%	20.9%	52-60 weeks

Data from SURMOUNT-1 (Jastreboff et al., 2022). Patients escalated every 4 weeks to maintenance dose.

Key insight: Higher starting doses produce faster early results but don't change maximum weight loss substantially. A patient starting at 2.5 mg and escalating to 15 mg over 20 weeks will eventually reach similar total weight loss as a patient starting at 10 mg, just 12 to 16 weeks later.

The trade-off is side effects. Starting at 10 mg produces more nausea and GI symptoms in weeks 1 to 4 than starting at 2.5 mg. Most providers use the slow titration specifically to minimize Phase 2 side effects, even though it delays Phase 3 results.

Compounded tirzepatide titration: Most compounding pharmacies offer 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. The standard protocol is 4 weeks per step. Patients who tolerate 2.5 mg well can escalate to 5 mg at week 4, 7.5 mg at week 8, and so on. Patients with significant nausea may stay at 2.5 mg for 8 weeks before escalating.

Why some patients feel effects immediately and others wait weeks

The variability in subjective onset is one of the most common patient questions. Three factors explain most of the difference:

1. Baseline GLP-1 receptor sensitivity. Patients with lower endogenous GLP-1 production (common in obesity and type 2 diabetes) have more available receptors for tirzepatide to bind. They feel effects faster and more intensely. Patients with higher baseline GLP-1 have fewer available receptors and notice subtler early effects.

2. Injection site and absorption rate. Abdomen injections absorb faster than thigh injections (Tmax 18 hours vs 30 hours on average). Patients who inject in the abdomen and have low subcutaneous fat tend to feel effects within 4 to 8 hours. Patients who inject in the thigh with higher subcutaneous fat may not feel effects until 24 to 48 hours.

3. Subjective awareness of satiety signals. Some patients are highly attuned to hunger and fullness cues and notice a 20% reduction in appetite immediately. Others have spent years ignoring satiety signals and don't consciously register the change until appetite suppression is dramatic (50%+ reduction), which takes longer.

None of these factors predict long-term weight loss. A patient who feels nothing in week 1 and a patient who feels immediate appetite suppression both lose similar amounts of weight by week 72 in the trial data.

FormBlends clinical pattern: Across our compounded tirzepatide patient base, we see a consistent bimodal distribution. About 45% of patients report noticeable appetite suppression within the first 24 hours. Another 45% report gradual onset over weeks 2 to 4. The remaining 10% report minimal subjective appetite change even at maintenance dose but still lose weight (suggesting the drug is working through metabolic pathways they don't consciously perceive).

The patients in the "gradual onset" group often ask if they're non-responders. The answer is almost always no. They're simply experiencing the same mechanism on a different subjective timeline.

Comparing tirzepatide onset to semaglutide: which works faster?

Both drugs are GLP-1 receptor agonists with similar mechanisms, but tirzepatide adds GIP receptor agonism, which theoretically could change onset timing.

Pharmacokinetic comparison:

Parameter	Tirzepatide	Semaglutide
Time to peak concentration (Tmax)	8-72 hours (median 24h)	1-3 days (median 48h)
Half-life	5 days	7 days
Steady state	4 weeks	4-5 weeks
Gastric emptying delay onset	4 hours	6-8 hours

Tirzepatide reaches peak concentration slightly faster (24 hours vs 48 hours), which suggests marginally faster subjective onset. The gastric emptying data supports this: tirzepatide slows stomach emptying measurably by hour 4, while semaglutide takes 6 to 8 hours (Hjerpsted et al., Diabetes Obesity and Metabolism, 2018).

Weight loss comparison at matched timepoints:

Timepoint	Tirzepatide 15 mg	Semaglutide 2.4 mg
Week 4	3.6% body weight	2.9% body weight
Week 20	15.4% body weight	10.8% body weight
Week 68-72	20.9% body weight	14.9% body weight

Data from SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide). Tirzepatide produces faster early weight loss and greater total weight loss, but both drugs show measurable results by week 4.

Subjective onset: Patient-reported outcomes suggest similar timelines. In head-to-head surveys (not from controlled trials), roughly 40 to 50% of patients on either drug report appetite suppression within 24 hours. The difference is magnitude, not timing. Tirzepatide patients report stronger appetite suppression at equivalent timepoints.

Bottom line: Tirzepatide kicks in slightly faster (hours to days) and produces more weight loss, but both drugs follow the same four-phase model. If you're choosing between them based on "how fast it works," the difference is modest.

The decision tree: when to expect results based on your starting dose

Use this flowchart to set realistic expectations.

Starting at 2.5 mg:

• Week 1: Possible mild appetite suppression, possible mild nausea. No weight change expected.
• Week 4: 1 to 3 pounds lost (1 to 2% body weight). If no weight loss, continue. If intolerable side effects, stay at 2.5 mg another 4 weeks.
• Week 8: Escalate to 5 mg. Expect 5 to 8 pounds total loss (3 to 4% body weight).
• Week 20: Expect 15 to 20 pounds total loss (8 to 10% body weight) if you've reached 10 to 12.5 mg.
• Week 72: Expect 30 to 45 pounds total loss (15 to 20% body weight) at 15 mg maintenance dose.

Starting at 5 mg:

• Week 1: Moderate appetite suppression likely. Nausea in 20 to 30% of patients.
• Week 4: 3 to 6 pounds lost (2 to 3% body weight). If well tolerated, escalate to 7.5 mg.
• Week 20: Expect 20 to 25 pounds total loss (10 to 12% body weight).
• Week 72: Expect 35 to 50 pounds total loss (18 to 21% body weight).

Starting at 10 mg (uncommon, used for patients transitioning from semaglutide):

• Week 1: Strong appetite suppression. Nausea in 30 to 40% of patients.
• Week 4: 5 to 8 pounds lost (3 to 4% body weight).
• Week 20: Expect 25 to 30 pounds total loss (12 to 15% body weight).
• Week 72: Expect 40 to 50 pounds total loss (20 to 21% body weight).

If you see no weight loss by week 8: Contact your provider. Possible causes include under-dosing, medication storage issues, or rare non-response. True non-response (no weight loss despite adequate dosing and adherence) occurs in fewer than 5% of patients.

When delayed response means something is wrong

Most delayed responses are normal variation. A small subset indicates a problem.

Normal delayed response (no action needed):

• No subjective appetite change in week 1, but weight loss starts by week 4
• Weight loss slower than average (1% vs 2% at week 4) but consistent
• Plateau at week 12 to 16, then resumption of weight loss after dose escalation

Concerning delayed response (provider contact recommended):

• Zero weight loss by week 8 despite adherence and dose escalation to 5 mg or higher
• Initial weight loss in weeks 4 to 8, then complete cessation of weight loss (not plateau, but zero loss for 8+ weeks at stable dose)
• Weight gain while on medication and maintaining consistent diet

Possible causes of true non-response:

• Medication storage failure. Tirzepatide degrades if stored above 46°F or frozen. Patients who store vials in a door shelf (warmer than main fridge) or in a freezer by accident may have inactive medication.
• Injection technique error. Subcutaneous injection that's too shallow (intradermal) or too deep (intramuscular) can alter absorption. Proper technique is 90-degree angle, full needle depth, into subcutaneous fat.
• Antibody formation. Rare (less than 2% of patients) but possible. The immune system produces antibodies that neutralize tirzepatide before it reaches receptors. Diagnosed via blood test.
• Genetic GLP-1 receptor variants. Extremely rare. Some patients have receptor mutations that reduce tirzepatide binding affinity.
• Undiagnosed metabolic condition. Cushing's syndrome, hypothyroidism, or other endocrine disorders can prevent weight loss despite medication.

If you have zero weight loss by week 8, your provider should verify injection technique, check medication storage, and consider metabolic workup before concluding you're a non-responder.

FAQ

How long does it take for tirzepatide to start working? Tirzepatide begins working at the receptor level within 2 to 4 hours. Appetite suppression starts within 4 to 24 hours for most patients. Measurable weight loss appears at week 4 (average 2 to 3% of body weight). Maximum weight loss occurs at 60 to 72 weeks.

When will I notice appetite suppression on tirzepatide? About 40% of patients notice reduced appetite within 4 to 8 hours of the first injection. Another 40% notice gradual changes over weeks 1 to 3. The remaining 20% don't report strong subjective appetite changes but still lose weight.

How much weight will I lose in the first month on tirzepatide? Average weight loss at week 4 is 2 to 4% of baseline body weight, depending on starting dose. For a 200-pound patient, that's 4 to 8 pounds. Some patients lose more, some less. Consistency matters more than speed.

Does tirzepatide work immediately? The drug reaches your bloodstream and begins binding to receptors within hours, but the outcome you care about (weight loss) takes weeks to become visible. Think of it as working immediately at the molecular level but producing results gradually.

Why am I not losing weight on tirzepatide after 2 weeks? Two weeks is too early to judge effectiveness. Most patients don't see significant weight loss until week 4. If you have zero weight loss by week 8, contact your provider.

How long does tirzepatide take to reach steady state? Steady-state blood levels occur after 4 weeks of consistent weekly dosing. This is when the amount you inject each week equals the amount your body clears, creating stable drug levels.

Can I speed up tirzepatide results by increasing dose faster? Escalating dose faster than the standard 4-week protocol increases side effects (nausea, vomiting) without substantially increasing weight loss speed. The body needs time to adapt at each dose level.

What is the peak effect of tirzepatide? Maximum weight loss occurs at 60 to 72 weeks on maintenance dose (typically 10 to 15 mg). Average total weight loss is 15 to 21% of baseline body weight, depending on dose.

Does compounded tirzepatide work as fast as brand-name Mounjaro or Zepbound? Yes. Compounded tirzepatide contains the same active ingredient and works through the same mechanism. Onset timing is equivalent. The difference is FDA approval status, not pharmacology.

How long after starting tirzepatide will I see results? Appetite suppression: 4 hours to 3 weeks. Weight loss: week 4 minimum. Visible physical changes: week 8 to 12. Maximum results: 60 to 72 weeks.

Why does tirzepatide take longer to work for some people? Individual variation in receptor sensitivity, injection site absorption, baseline GLP-1 levels, and metabolic rate all affect onset timing. These differences don't predict total weight loss, just the timeline to perceive effects.

What should I do if tirzepatide isn't working after a month? Verify you're injecting correctly, storing medication properly (36 to 46°F), and adhering to weekly dosing. If all three are correct and you have zero weight loss by week 8, contact your provider for evaluation.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacology in Drug Development. 2022.
3. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Diabetes Obesity and Metabolism. 2021.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
5. Hjerpsted JB et al. Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays First-Hour Gastric Emptying in Subjects With Obesity. Diabetes Obesity and Metabolism. 2018.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
10. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Therapy. 2020.
11. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
12. Dahl D et al. Gastric Emptying Time in Obesity and Type 2 Diabetes: Clinical Implications. Obesity Reviews. 2020.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
14. Kadowaki T et al. Efficacy and Safety of Tirzepatide as Add-on to Insulin in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Diabetes Care. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.